Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EIF2AK2 (PKR) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EIF2AK2 (PKR) Active Kinase / Kinase-Dead Mutant (K296R) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for enzymatic assays. |
View EIF2AK2 Products |
| Gene Delivery | EIF2AK2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation. |
View EIF2AK2 Products |
| Benchmark Ab | Anti-EIF2AK2 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View EIF2AK2 Products |
| Validator | EIF2AK2 siRNA Set For knockdown verification in functional phenotypic assays. |
View EIF2AK2 Products |
| Related Target A | EIF2S1 (eIF2α) Direct downstream substrate of EIF2AK2; critical for phosphorylation assays. |
View EIF2S1 Products |
| Related Target B | EIF2AK3 (PERK) Key homologous eIF2α kinase; required for counter-screening to ensure selectivity. |
View EIF2AK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against homologous kinases | Recombinant EIF2AK3 (PERK), EIF2AK4 (GCN2), and EIF2AK1 (HRI) proteins available for strict counter-screening. |
| ATP-competitive assay interference | Kinase-dead mutant (K296R) available as a definitive negative control to exclude assay artifacts. |
| Lack of Controls | Sequence-verified clinical benchmark recombinant antibodies included. |
| False Positives | Validated siRNA sets included for orthogonal target knockdown verification. |
Live EIF2AK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EIF2AK2 (PKR) therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum kinase inhibition to highly selective small molecule inhibitors and activators. EIF2AK2 plays a dual role: its inhibition is highly sought after in neurodegenerative diseases (such as Alzheimer's disease and ALS) to prevent neuroinflammation and neuronal apoptosis, while its activation is being leveraged in oncology to induce immunogenic cell death (ICD) and synergize with immune checkpoint inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting allosteric modulation and tissue-specific delivery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Inhibitor Developers | Alzheimer's, ALS, Neuroinflammation | High-throughput kinase assay (Need highly active EIF2AK2 and EIF2S1 substrate) |
| Small Molecule Activator | Oncology Biotechs | Solid Tumors, Viral Infections | Allosteric binding assays (Need sequence-verified full-length active protein) |
| Gene Therapy / siRNA | RNAi Therapeutics Companies | Inflammatory Diseases | In vitro knockdown verification (Need validated EIF2AK2 siRNA) |